Supplemental Table S1.

			Standard washout		Expanded washout	
		Timepoint	pCrkL (% of untreated MFI)	pSTAT5 (% of untreated MFI)	pCrkL (% of untreated MFI)	pSTAT5 (% of untreated MFI)
dasatinib	10 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	12.6%	14.8%	12.2%	22.0%
		8 h post washout	93.0%	71.4%	131.4%	104.4%
		24 h post washout	77.9%	74.9%	130.3%	112.4%
	100 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	1.9%	7.7%	2.8%	16.2%
		8 h post washout	78.5%	17.5%	87.6%	41.2%
		24 h post washout	58.0%	7.1%	68.3%	35.4%
ponatinib	10 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	15.2%	14.7%	31.2%	25.2%
		8 h post washout	74.9%	23.6%	83.8%	38.2%
		24 h post washout	34.3%	8.7%	76.0%	24.6%
	100 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	1.9%	6.5%	3.2%	15.9%
		8 h post washout	9.4%	9.1%	26.4%	21.9%
		24 h post washout	0.4%	1.7%	6.0%	6.0%
nilotinib	500 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	5.8%	7.2%	7.5%	12.6%
		8 h post washout	80.9%	33.0%	100.4%	111.8%
		24 h post washout	78.2%	33.5%	105.6%	101.4%
	5000 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	3.4%	1.7%	3.9%	7.6%
		8 h post washout	14.0%	5.7%	80.6%	20.1%
		24 h post washout	10.3%	1.5%	68.6%	16.7%
imatinib	500 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	61.8%	19.6%	63.8%	25.8%
		8 h post washout	115.4%	138.1%	113.7%	213.3%
		24 h post washout	118.4%	97.8%	108.2%	97.1%
	5000 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	6.8%	3.6%	9.4%	9.1%
		8 h post washout	77.9%	115.9%	123.6%	175.4%
		24 h post washout	76.2%	74.1%	136.8%	91.8%
DCC-2036	500 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	5.1%	6.7%	6.2%	12.5%
		8 h post washout	91.6%	61.5%	92.2%	102.5%
		24 h post washout	90.3%	73.9%	98.6%	95.7%
	5000 nM	Untreated	100.0%	100.0%	100.0%	100.0%
		End of washout	0.9%	2.0%	1.2%	6.5%
		8 h post washout	62.6%	32.5%	114.8%	71.8%
		24 h post washout	65.9%	46.6%	132.8%	90.9%

NOTE: Percent of untreated mean fluorescence intensity (MFI) values were calculated as follows: ([stained MFI] - [isotype MFI]) / ([stained MFI for untreated cells] - [isotype MFI for untreated cells]) x 100. Graphical representation of each value is shown immediately to the the right, with red dashed lines provided as a reference to the level of untreated controls.

Supplemental Table S2.

ABL kinase:inhibitor dissociation		
Inhibitor	Active $t_{1/2}$ (h)	Inactive $t_{1/2}$ (h)
dasatinib	30	6.8
ponatinib	>48	>48
nilotinib	10	>48
imatinib	0.029	0.76
DCC-2036	26	>48
staurosporine	<0.017	<0.017